C Bokemeyer

Summary

Affiliation: University of Hamburg
Country: Germany

Publications

  1. ncbi Micro-RNA expression in cisplatin resistant germ cell tumor cell lines
    Matthias Port
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
    Mol Cancer 10:52. 2011
  2. ncbi Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway
    Leticia Oliveira-Ferrer
    Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Exp Clin Cancer Res 27:86. 2008
  3. ncbi Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
    Jan K Hennigs
    Centre for Pulmonary Hypertension, University Medical Centre Hamburg Eppendorf, 20246 Hamburg, Germany
    BMC Pulm Med 11:30. 2011
  4. ncbi Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    BMC Cancer 9:311. 2009
  5. ncbi EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
    C Bokemeyer
    Universitaetsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany, and Department of Haematology, Karolinska University Hospital, Stockholm, Sweden
    Eur J Cancer 43:258-70. 2007
  6. ncbi Anaemia in cancer patients: pathophysiology, incidence and treatment
    C Bokemeyer
    Department of Oncology, Haematology, Bone Marrow, Transplantation and Pneumology, University of Eppendorf Medical Center, Hamburg, Germany
    Eur J Clin Invest 35:26-31. 2005
  7. ncbi Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    Carsten Bokemeyer
    University Hospital, Hamburg Eppendorf, Hamburg Eppendorf, Germany
    J Clin Oncol 27:663-71. 2009
  8. ncbi Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites
    Carsten Bokemeyer
    Universitatsklinikum Hamburg Eppendorf, Department of Oncology, Hematology, BMT With Section Pneumology, Hamburg, Germany
    Expert Opin Biol Ther 10:1259-69. 2010
  9. ncbi Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
    C Bokemeyer
    Department of Oncology, Hematology, BMT With Section Pneumology, University Hospital, Hamburg Eppendorf, Germany
    Ann Oncol 22:1535-46. 2011
  10. ncbi Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy
    K Oechsle
    Department of Oncology, University Medical Center Eppendorf, Hamburg, Germany
    Eur J Cancer 44:1663-9. 2008

Detail Information

Publications69

  1. ncbi Micro-RNA expression in cisplatin resistant germ cell tumor cell lines
    Matthias Port
    Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
    Mol Cancer 10:52. 2011
    ..We compared microRNA expression patterns in three cisplatin resistant sublines derived from paternal cisplatin sensitive germ cell tumor cell lines in order to improve our understanding of the mechanisms of cisplatin resistance...
  2. ncbi Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway
    Leticia Oliveira-Ferrer
    Department of Oncology and Hematology with Section Pneumology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Exp Clin Cancer Res 27:86. 2008
    ..Aim of the current study was to investigate effects of cilengitide on endothelial and glioma cells on molecular and cellular levels...
  3. ncbi Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
    Jan K Hennigs
    Centre for Pulmonary Hypertension, University Medical Centre Hamburg Eppendorf, 20246 Hamburg, Germany
    BMC Pulm Med 11:30. 2011
    ..Encouraging efforts have been made to target the main vasoproliferative aspects of the disease. Promising emerging therapeutics are tyrosine kinase inhibitors such as imatinib...
  4. ncbi Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial
    Johan Vansteenkiste
    Respiratory Oncology Unit Pulmonology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    BMC Cancer 9:311. 2009
    ..In the European Union and United States, ESA therapy initiation for CIA is now recommended at a Hb level < or = 10 g/dL. The present exploratory analysis examined how ESA initiation at this Hb level may impact patient care...
  5. ncbi EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
    C Bokemeyer
    Universitaetsklinikum Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany, and Department of Haematology, Karolinska University Hospital, Stockholm, Sweden
    Eur J Cancer 43:258-70. 2007
    ..While our review did not address cost benefit evaluations in detail, the consensus is that studies taking into account all real determinants of cost and benefit need to be performed prospectively...
  6. ncbi Anaemia in cancer patients: pathophysiology, incidence and treatment
    C Bokemeyer
    Department of Oncology, Haematology, Bone Marrow, Transplantation and Pneumology, University of Eppendorf Medical Center, Hamburg, Germany
    Eur J Clin Invest 35:26-31. 2005
    ..Finally, differences in treatment approaches between these erythropoietic proteins are discussed in order to guide treatment decisions specific for the individual patients' situation...
  7. ncbi Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    Carsten Bokemeyer
    University Hospital, Hamburg Eppendorf, Hamburg Eppendorf, Germany
    J Clin Oncol 27:663-71. 2009
    ..The influence of KRAS mutation status was investigated...
  8. ncbi Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites
    Carsten Bokemeyer
    Universitatsklinikum Hamburg Eppendorf, Department of Oncology, Hematology, BMT With Section Pneumology, Hamburg, Germany
    Expert Opin Biol Ther 10:1259-69. 2010
    ..The European Medicines Agency (EMA) approved the use of a trifunctional bispecific antibody, catumaxomab (Removab), for the intraperitoneal (i.p.) treatment of malignant ascites in April 2009...
  9. ncbi Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
    C Bokemeyer
    Department of Oncology, Hematology, BMT With Section Pneumology, University Hospital, Hamburg Eppendorf, Germany
    Ann Oncol 22:1535-46. 2011
    ....
  10. ncbi Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy
    K Oechsle
    Department of Oncology, University Medical Center Eppendorf, Hamburg, Germany
    Eur J Cancer 44:1663-9. 2008
    ..Retrospective analysis of characteristics and outcome of germ cell tumour (GCT) patients with cerebral metastases (CM) undergoing high-dose chemotherapy (HD-CTX) or relapsing with CM...
  11. ncbi Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group
    C Bokemeyer
    Department of Oncology Hematology, University Medical Centre Eppendorf, Hamburg, Germany
    Ann Oncol 19:448-53. 2008
    ..The aim of this study is to determine feasibility and efficacy of the combination regimen gemcitabine, oxaliplatin, and paclitaxel (GOP) in patients with cisplatin-refractory or multiply relapsed germ-cell tumors...
  12. ncbi Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study
    K Oechsle
    Division of Oncology, Hematology, Bone Marrow Transplantation and Section Pneumology, University Medical Centre Eppendorf, Hamburg University, Germany
    Ann Oncol 22:2654-60. 2011
    ..The objective of the study was to investigate the activity of sunitinib in a cell line model and subsequently in patients with cisplatin-refractory or multiply relapsed germ cell tumors (GCT)...
  13. ncbi Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy)
    G Schilling
    Onkologisches Zentrum, II Medizinische Klinik und Poliklinik, Universitatsklinikum Hamburg Eppendorf, Martinistr 52, 20246, Hamburg, Germany
    Invest New Drugs 27:166-72. 2009
    ..This phase II trial of vinorelbine and trastuzumab demonstrated an effective and well-tolerated regimen with a favourable safety profile...
  14. ncbi Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update
    D Koychev
    Universitatsklinikum Hamburg Eppendorf, Hubertus Wald Tumorcenter, Oncology, Haematology and Bone Marrow Transplantation with Section Pulmology, Hamburg, Germany
    Int J Androl 34:e266-73. 2011
    ..Currently, a number of mechanisms of cisplatin resistance and potential drug targets like global methylation and BRAF mutation status are under investigation in refractory GCT...
  15. ncbi Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients
    S Kobold
    1 Department of Oncology, Hematology, Stem Cell Transplantation with the section Pneumology, Department of Internal Medicine II, University Cancer Center Hamburg Hubertus Wald Tumorzentrum, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Bone Marrow Transplant 46:1053-6. 2011
    ..Accordingly, plerixafor seems to be safe and effective in germ cell tumor patients who have failed prior mobilization therapy. Larger prospective studies are warranted to further assess its use in germ cell cancer...
  16. ncbi HER-2/neu analysis in breast cancer bone metastases
    J Zustin
    Institute of Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Clin Pathol 62:542-6. 2009
    ..HER-2 can be analysed by fluorescence in situ hybridisation (FISH) for gene amplification or immunohistochemistry (IHC) for protein overexpression...
  17. ncbi [Haemostatic aspects in clinical oncology]
    F Langer
    Onkologisches Zentrum, II Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Hamburg
    Hamostaseologie 28:472-80. 2008
    ....
  18. ncbi [A multi-disciplinary approach to the treatment of germ cell tumors]
    F Honecker
    Onkologisches Zentrum, II Medizinische Klinik und Poliklinik, Hubertus Wald Tumorzentrum, Universitäres Cancer Center Hamburg UCCH, Universitatsklinikum Hamburg Eppendorf, Martinistrase 52, 20246, Hamburg
    Internist (Berl) 51:1382-7. 2010
    ..Complex cases with poor prognosis and all patients with relapsed disease should exclusively be treated by experts in a tertiary care setting to achieve highest possible cure rates in these young patients...
  19. ncbi An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
    J T Hartmann
    Department of Medical Oncology, Hematology, Immunology, Rheumatology, Pneumology, South West German Cancer Center, Eberhard Karls University, Tuebingen, Germany
    Invest New Drugs 24:249-53. 2006
    ..The aim of this trial was to evaluate the efficacy of gemcitabine in this setting...
  20. ncbi Gene amplification in ductal carcinoma in situ of the breast
    L Burkhardt
    Department of Pathology, University Medical Center Hamburg Eppendorf, Martinistr 52, 20246, Hamburg, Germany
    Breast Cancer Res Treat 123:757-65. 2010
    ..Therefore, our data suggest an early role of all analyzed gene amplifications in breast cancer development but not in the initiation of invasive tumor growth...
  21. ncbi Successful eradication of a FVIII inhibitor in a 60-year-old patient with mild haemophilia A using single-agent prednisolone
    K Holstein
    II Medizinische Klinik und Poliklinik, Universitatsklinikum Hamburg Eppendorf, Hamburg, Germany
    Hamostaseologie 32:S48-51. 2012
    ..Development of FVIII inhibitors represents a major challenge in patients with mild haemophilia A (HA), because they tend to occur at an older age and classical immune tolerance induction appears to be less effective...
  22. ncbi Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor
    F Langer
    Hubertus Wald Tumorzentrum Universitäres Cancer Center Hamburg, Universitatsklinikum Hamburg Eppendorf, Hamburg
    Hamostaseologie 32:95-104. 2012
    ....
  23. ncbi Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients
    J Panse
    Department of Oncology Hematology, Center of Oncology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, Hamburg 20246, Germany
    Br J Cancer 99:930-8. 2008
    ....
  24. ncbi Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
    G Schilling
    Department of Oncology and Hematology, Medical Clinic II, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Leukemia 22:1250-5. 2008
    ..Translocation t(4;14) might be overcome by allogeneic HSCT, which will have implication for risk-adapted strategies...
  25. ncbi Phase I trial of SU14813 in patients with advanced solid malignancies
    W Fiedler
    Department of Oncology, Hematology, BMT With Section Pneumology, Hubertus Wald Tumorzentrum, University Cancer Center Hamburg, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Ann Oncol 22:195-201. 2011
    ..this phase I, open-label, dose-escalation study investigated SU14813, an oral multitargeted tyrosine kinase inhibitor, in adults with solid tumors...
  26. ncbi Experimental metastasis and primary tumor growth in mice with hemophilia A
    F Langer
    II Medizinische Klinik und Poliklinik, Universitätsklinikum Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    J Thromb Haemost 4:1056-62. 2006
    ..Although TF expression by B16F10 cells may promote thrombin-dependent metastasis in mice with hemophilia A, amplification of coagulation by host FVIII appears to be necessary for maximum lung seeding...
  27. ncbi Antiangiogenic treatment with endostatin inhibits progression of AML in vivo
    G Schuch
    Department of Medicine, Oncology and Hematology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Leukemia 19:1312-7. 2005
    ..Taken together, ES has inhibitory effects on neo-angiogenesis in the bone marrow and on progression of leukemia in vivo. These experiments suggest a possible therapeutic role of antiangiogenic gene therapy with ES in AML...
  28. ncbi Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer
    J Wierecky
    Department of Oncology, Hematology, Immunology, and Rheumatology, Medizinische Klinik, University of Tuebingen Medical Center, Otfried-Mueller-Strasse 10, 72076 Tuebingen, Germany
    J Cancer Res Clin Oncol 131:255-60. 2005
    ..No solid tumors had occurred.CONCLUSIONS: HDCT including high-dose etoposide with autologous PBSCT as first-line therapy for advanced testicular cancer was associated with an acceptably low risk of developing secondary leukemia...
  29. ncbi Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro
    S Koch
    Department of Oncology, Hematology, Immunology, and Rheumatology, Medizinische Klinik, , , Tuebingen 72076, Germany
    Br J Cancer 89:2133-9. 2003
    ....
  30. ncbi Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors
    F Mayer
    Department of Oncology, Hematology, Immunology and Rheumatology, , , Germany
    Ann Oncol 14:825-32. 2003
    ..Even though no uniform pattern of relevant resistance factors has been identified in patients suffering from refractory disease, a significant number of these cases may be caused by defects in the DNA mismatch repair pathway...
  31. ncbi [Development of angiogenesis inhibitory combination therapies for treatment of renal cell carcinoma]
    G Bartsch
    , , Prittwitzstrasse 43, 89075 Ulm
    Urologe A 46:1289-90. 2007
  32. ncbi EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
    C Bokemeyer
    Universitaetsklinikum Tuebingen, Medizinische Klinik Abteilung II, Otfried Mueller St 10, D 72076 Tuebingen, Germany
    Eur J Cancer 40:2201-16. 2004
    ..Additional trials are warranted, especially on the issues of iron replacement and cost-effectiveness of erythropoietic protein therapy, as well as on tumour response/progression and survival...
  33. ncbi Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy
    C Bokemeyer
    Abteilung Hamatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Germany
    Onkologie 25:32-9. 2002
    ....
  34. ncbi Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastroint
    C H Kohne
    Department og Internal Medicine I, University of Dresden, Dresden, Germany
    J Clin Oncol 21:3721-8. 2003
    ..This trial was conducted to determine whether high-dose fluorouracil (FU) given as a weekly 24-hour infusion is more active than bolus FU + leucovorin (LV), and whether high-dose infusional FU can be modulated by LV...
  35. ncbi [Compression syndromes]
    J Wierecky
    , Onkologie, Immunologie und Rheumatologie, Medizinische Klinik II,
    Internist (Berl) 46:9-18. 2005
    ..MRI should be preferred in the diagnostic work-up, corticosteroids be administered promptly after biopsy. Radiation therapy or surgical treatment should be started as soon as possible...
  36. ncbi Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    Ann Oncol 13:1017-28. 2002
    ..This investigation evaluates prognostic variables in patients with seminomatous and non-seminomatous extragonadal germ-cell tumors (EGCT) in order to identify relevant factors for long-term outcome following cisplatin-based chemotherapy...
  37. ncbi Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
    C Kollmannsberger
    Department of Haematology Oncology, University of Tuebingen Medical Center, Germany
    Br J Cancer 87:729-32. 2002
    ..Irinotecan at a dose of 300-350 mg m(-2) every 3 weeks appears to have no antitumour activity in patients with cisplatin-refractory germ cell cancer and, thus, further investigation in this disease is not justified...
  38. ncbi [Allogeneic hematopoetic cell transplantation in patients with solid tumors - Contra]
    C Bokemeyer
    , Onkologie, Immunologie und Rheumatologie,
    Dtsch Med Wochenschr 127:2215. 2002
  39. ncbi Impact of tumor size on the long-term survival of patients with early stage renal cell cancer
    M Kuczyk
    Department of Urology, Eberhard Karls University, Hoppe Seyler Strasse 3, 72076 Tubingen, Germany
    World J Urol 23:50-4. 2005
    ..The present study demonstrates the need for multivariate statistical approaches when the latest modification of the TNM classification system is critically evaluated...
  40. ncbi Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer
    C Bokemeyer
    Department of Haematology Oncology, University of Tuebingen Medical Centre, Otfried Muller Strasse 10, 72076 Tuebingen, Germany
    Br J Cancer 87:1066-71. 2002
    ..Despite the frequent use of red blood cell transfusions, median haemoglobin nadirs remained about 7.5-8 g dl(-1) during therapy. A correlation of haemoglobin-values after completion of therapy to overall treatment outcome was found...
  41. ncbi Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer
    O Rick
    Department of Hematology, , Campus Virchow Klinikum, Berlin, Germany
    J Clin Oncol 19:81-8. 2001
    ..Peripheral nervous toxicity in approximately one third of patients is a disadvantage of this salvage strategy...
  42. ncbi Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer
    C Kollmannsberger
    Department of Internal Medicine, University of Tuebingen Medical Center, Tuebingen, Germany
    Cancer 95:301-8. 2002
    ..The lack of differences between the tumors of refractory and the responsive patients indicates that overexpression of any of these receptor tyrosine kinases does not contribute to a resistant phenotype in GCTs...
  43. ncbi A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors
    F Mayer
    , , Immunologie und Rheumatologie, , Germany
    Ann Oncol 13:755-9. 2002
    ..The recommended doses for phase II studies are 300 mg/m2 of UFT plus 90 mg of folinic acid on days 1-28, and 90 mg/m2 of paclitaxel weekly...
  44. ncbi [Therapy of elderly patients with colorectal carcinoma]
    F Honecker
    , Onkologie,
    Wien Med Wochenschr 152:170-6. 2002
    ..It is the aim of this manuscript to summarize the current knowledge about the management of colorectal cancer in elderly patients...
  45. ncbi Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer
    F Honecker
    Department of Hematology/Oncology, , , Germany
    Anticancer Drugs 13:497-503. 2002
    ..Other organ toxicities apart from a slightly higher incidence of peripheral neuropathy were comparable between the two treatment protocols. Efficacy with a response rate of 50% was well preserved by this weekly regimen...
  46. ncbi Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation--a phase II study
    A Jakob
    Department of Hematology/Oncology, , Otfried-Mueller-Strasse 10, , Germany
    Anticancer Drugs 13:405-10. 2002
    ..It can be safely used in patients who have been intensively pretreated by myelotoxic chemotherapy or who have even relapsed after high-dose chemotherapy with PBSCT...
  47. ncbi Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group
    C Kollmannsberger
    Department of Hematology/Oncology, University of Tuebingen Medical Center, Tuebingen, Germany
    J Clin Oncol 20:2031-7. 2002
    ..Oxaliplatin may be a palliative treatment option for this patient population, and evaluation in combination regimens is warranted...
  48. ncbi [Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?]
    F Honecker
    Abteilunh Hämatologie, Onkologie, Rheumatologie und Immunologie, Medizinische Universitätsklinik Tübingen, Tubingen
    Onkologie 24:87-94. 2001
    ..Further clinical trials of chemotherapy in elderly patients with colorectal cancer are necessary to gain information about treatment recommendations...
  49. ncbi Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy
    C Kollmannsberger
    Department of Medicine II, University of Tuebingen, Otfried-Mueller-Str. 10, 72076 Tuebingen, Germany
    World J Urol 19:120-5. 2001
    ..It is hoped that the increase in knowledge of the molecular mechanism of testicular cancer may lead to the development of new therapeutic options...
  50. ncbi Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome
    C Bokemeyer
    Tuebingen University Medical Center II, Tuebingen, Germany
    Cancer 91:1394-401. 2001
    ..Primary radiotherapy seems to be associated with a significantly higher rate of disease recurrence, although most patients will be salvaged by subsequent chemotherapy...
  51. ncbi Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    Anticancer Res 23:1899-901. 2003
    ..The number of cytostatic agents effective in patients with advanced soft tissue sarcoma is limited. Trofosfamide, an alkylating agent, has been shown to be effective in several solid and haematological tumors...
  52. ncbi Current aspects of high-dose chemotherapy in germ-cell tumors
    O Rick
    , , Campus Mitte, , Schumann Str. 20/21, 10117 Berlin, Germany
    Crit Rev Oncol Hematol 47:237-48. 2003
    ..Prognostic factors have recently been recognized to aid in this decision...
  53. ncbi Pharmacotherapy of relapsed metastatic testicular cancer
    C Kollmannsberger
    British Columbia Cancer Agency University of British Columbia Vancouver Cancer Centre, Division of Medical Oncology, 600 West 10th Avenue, Vancouver, BC V5Z4E6, Canada
    Expert Opin Pharmacother 9:2259-72. 2008
    ..Patients with metastatic testicular cancer exhibit an excellent prognosis. However, the outcome for patients with relapse after cisplatin-based chemotherapy remains unsatisfactory. Several larger studies have been recently published...
  54. ncbi Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO
    C Kollmannsberger
    Department of Hematology/Oncology, Department of Radiation Oncology, University of Tuebingen, Tuebingen
    Ann Oncol 16:1326-33. 2005
    ..Treatment should be given in experienced centres in order to avoid unnecessary toxicity...
  55. ncbi Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986
    C H Kohne
    Department of Internal Medicine, University of Dresden, Dresden
    J Clin Oncol 23:4856-65. 2005
    ..To demonstrate that adding irinotecan to a standard weekly schedule of high-dose, infusional fluorouracil (FU) and leucovorin (folinic acid [FA]) can prolong progression-free survival (PFS)...
  56. ncbi [Chemotherapy for germ cell cancer]
    J Beyer
    Klinik für Hämatologie, Onkologie und Immunologie, Klinikum der Philipps Universität, Marburg
    Urologe A 43:1507-13. 2004
    ..If excessive toxicity is to be avoided and a curative treatment option maintained, overtreatment as well as undertreatment are notorious pitfalls...
  57. ncbi Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC)
    F Honecker
    , Onkologie, Rheumatologie und Immunologie, , Germany
    Onkologie 27:583-8. 2004
    ..A review of the most important trials, assessing treatment options in elderly patients with lung cancer, either prospectively or retrospectively, is provided, and still unresolved issues are addressed...
  58. ncbi A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
    C Kollmannsberger
    Department of Hematology/Oncology, University of Tuebingen, Germany
    Ann Oncol 17:1007-13. 2006
    ..CONCLUSIONS: Matuzumab doses up to 800 mg weekly with paclitaxel 175 mg/m(2) every 3 weeks are well tolerated, with no apparent drug interactions and with evidence of antitumor activity...
  59. ncbi A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane
    J A Ajani
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas, 77030, USA
    Invest New Drugs 24:441-6. 2006
    ..With the primary endpoint of assessing ixabepilone's response rate against metastatic gastric cancer previously treated with a taxane, we performed a multi-center phase II trial...
  60. ncbi Chemotherapy in elderly patients with advanced lung cancer. Part I: General aspects and treatment of small cell lung cancer (SCLC)
    F Honecker
    , Onkologie, Rheumatologie und Immunologie, , Germany
    Onkologie 27:500-5. 2004
    ..Further evaluation of these topics is needed, and can be achieved by trials specifically designed for elderly patients or patients with reduced performance status...
  61. ncbi Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials
    C Bokemeyer
    Department of Hematology Oncology, University of Tuebingen, Otfried Mueller Str 10, 72076 Tuebingen, Germany
    Br J Cancer 91:683-7. 2004
    ..In conclusion, carboplatin single agent therapy cannot be recommended as standard treatment for any patient subgroup with advanced metastatic seminoma and cisplatin-based combination regimens remain the standard of care...
  62. ncbi Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial
    R D Hofheinz
    Onkologisches Zentrum, III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Theodor Kutzer Ufer, D 68167 Mannheim, Germany
    Br J Cancer 91:834-8. 2004
    ..The favourable safety profile and promising activity of the capecitabine/mitomycin C combination, even in heavily pretreated patients, warrant further evaluation in patients with advanced colorectal and gastric cancers...
  63. ncbi Salvage chemotherapy for metastatic breast cancer: results of a phase II study with bendamustine
    U Reichmann
    Department of Radiooncology, University of Tuebingen, Tuebingen, Germany
    Ann Oncol 18:1981-4. 2007
    ..This multicenter phase II trial defines the toxicity and activity of bendamustine in heavily pretreated patients...
  64. ncbi The role of high-dose chemotherapy in relapsed germ cell tumors
    O Rick
    Medizinische Klinik II m S Onkologie Hämatologie, Universitatsklinikum Charite, Campus Mitte, Humboldt Universitat, Schumannstrasse 20 21, 10117 Berlin, Germany
    World J Urol 22:25-32. 2004
    ..This report reviews the current treatment strategies and recent developments with respect to HDCT given as salvage treatment and discusses the role of prognostic factors in the management of such situations...
  65. ncbi Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study
    J T Hartmann
    Abt Hämatologie Onkologie Immunologie Rheumatologie, Medizinische Klinik II, Eberhard Karls Universitat, Tuebingen, Germany
    Br J Cancer 89:2051-6. 2003
    ..In gastric cancer,MMC plus infusional 5-FU/folinic acid may be a potential second-line regimen with promising antitumour activity...
  66. ncbi Modern treatment options for elderly patients with multiple myeloma
    Martin Görner
    Klinik für Hämatologie und Onkologie, Städtische Kliniken Bielefeld gGmbH, Bielefeld, Germany
    Onkologie 31:335-42. 2008
    ..In this review, we discuss the data available from clinical trials investigating antineoplastic treatment of elderly multiple myeloma patients...
  67. ncbi Stem cell factor as a novel diagnostic marker for early malignant germ cells
    H Stoop
    Department of Pathology, Erasmus MC Erasmus University Medical Center, Daniel den Hoed Cancer Center, Josephine Nefkens Institute, Rotterdam, The Netherlands
    J Pathol 216:43-54. 2008
    ..SCF immunohistochemistry can be a valuable diagnostic tool, in addition to OCT3/4, to screen for precursor lesions of TGCTs, especially in patients with germ cell maturation delay...
  68. ncbi Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer S
    H J Schmoll
    Department of Hematology Oncology, University of Halle, Halle, Germany
    J Clin Oncol 21:4083-91. 2003
    ..This analysis reports toxicity and long-term results of a large phase I/II study of sequential high-dose etoposide, ifosfamide, and cisplatin (VIP) in patients with advanced germ cell tumors...
  69. ncbi Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis
    J T Hartmann
    Tuebingen University Medical Center II, Tuebingen, Germany
    J Clin Oncol 19:1641-8. 2001
    ....